Clinical trial
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg…
NCT00379613 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00379613 |
|---|---|
| Title | Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) |
| Official title | A Multi-Center Randomized Safety Assessor-Blinded Placebo-Controlled Parallel and Dose Escalating Dose-Finding Trial in Subjects of ASA 1 - 2 to Assess the Safety, Efficacy and PK of Sugammadex Administered at 5 Min. After Administration of 1.2 mg/kg Esmeron |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anesthesia, General |
| Intervention type | Drug |
| Interventions | sugammadex, Placebo |
| Enrollment | 45 |
| Start date | Nov 7, 2003 |
| Primary completion | Jul 14, 2004 |
| Completion | Jul 14, 2004 |
| First posted | Sep 22, 2006 |
| Last update posted | Aug 22, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: